Franz L Ricklefs

List of Publications by Year
in descending order

135 papers	5,825 citations	218677 26 h-index	82547 72 g-index
136 all docs	136 docs citations	136 times ranked	9080 citing authors

#	Article	IF	Citations
1	Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling. Child's Nervous System, 2022, 38, 479-483.	1.1	3
2	Primary central nervous system sarcoma with *DICER1* mutation—treatment results of a novel molecular entity in pediatric Peruvian patients. Cancer, 2022, 128, 697-707.	4.1	14
3	Machine learning models predict the primary sites of head and neck squamous cell carcinoma metastases based on DNA methylation. Journal of Pathology, 2022, 256, 378-387.	4.5	19
4	The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2. Stem Cell Reports, 2022, 17, 307-320.	4.8	138
5	MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays. Cell Reports Methods, 2022, 2, 100136.	2.9	8
6	Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. European Journal of Cancer, 2022, 162, 221-236.	2.8	22
7	ALK inhibition as a salvage therapy for a relapsed unclassifiable sarcomatous CNS tumor with EML4/ALK fusion in an infant. Pediatric Blood and Cancer, 2022, 69, e29594.	1.5	0
8	Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies. Journal of Neuro-Oncology, 2022, 157, 37-48.	2.9	2
9	Single-cell transcriptomics identifies potential cells of origin of MYC rhabdoid tumors. Nature Communications, 2022, 13, 1544.	12.8	9
10	Updates in the classification of ependymal neoplasms: The 2021 WHO Classification and beyond. Brain Pathology, 2022, 32, e13068.	4.1	29
11	Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease. Neuro-Oncology, 2022, 24, 1689-1699.	1.2	11
12	Increased replication stress and R-loop accumulation in EGFRvIII-expressing glioblastoma present new therapeutic opportunities. Neuro-Oncology Advances, 2022, 4, vdab180.	0.7	2
13	Disruption of GMNC-MCIDAS multiciliogenesis program is critical in choroid plexus carcinoma development. Cell Death and Differentiation, 2022, 29, 1596-1610.	11.2	7
14	SMARCB1-deficient and SMARCA4-deficient Malignant Brain Tumors With Complex Copy Number Alterations and TP53 Mutations May Represent the First Clinical Manifestation of Li-Fraumeni Syndrome. American Journal of Surgical Pathology, 2022, 46, 1277-1283.	3.7	3
15	DNA methylation subclass receptor tyrosine kinase II (RTK II) is predictive for seizure development in glioblastoma patients. Neuro-Oncology, 2022, 24, 1886-1897.	1.2	7
16	Diagnostic potential of extracellular vesicles in meningioma patients. Neuro-Oncology, 2022, 24, 2078-2090.	1.2	6
17	MEDB-50. Assessment of cellular radiosensitivity and DNA repair in medulloblastoma cell lines and patient-derivded xenograft slice cultures. Neuro-Oncology, 2022, 24, i117-i118.	1.2	0
18	ATRT-12. LIN28A expression correlates with poor prognosis and the MYC subgroup in AT/RTs. Neuro-Oncology, 2022, 24, i5-i5.	1.2	0

#	Article	IF	Citations
19	EPEN-13. Clinically relevant molecular hallmarks of PFA ependymomas display intratumoral heterogeneity and correlate with tumor morphology. Neuro-Oncology, 2022, 24, i41-i41.	1.2	0
20	OTHR-41. Amplification of the PLAG family genes â€" PLAGL1 and PLAGL2 â€" is a key feature of a novel embryonal CNS tumor type. Neuro-Oncology, 2022, 24, i156-i156.	1.2	1
21	ETMR-05. Single-cell transcriptomics of ETMR reveals developmental cellular programs and tumor-pericyte communications in the microenvironment. Neuro-Oncology, 2022, 24, i50-i50.	1.2	0
22	EPEN-19. Impact of molecular classification on prognosis in children and adolescents with spinal ependymoma: Results from the HIT-MED database. Neuro-Oncology, 2022, 24, i42-i43.	1.2	0
23	ETMR-06. Molecular and clinical characteristics of CNS tumors with*BCOR(L1*) fusion/internal tandem duplication. Neuro-Oncology, 2022, 24, i50-i50.	1.2	2
24	MEDB-37. Chemotherapy response prediction by molecular risk factors in metastatic childhood medulloblastoma. Neuro-Oncology, 2022, 24, i113-i113.	1.2	0
25	MEDB-41. Identifying a subgroup of patients with early childhood sonic hedgehog-activated medulloblastoma with unfavorable prognosis after treatment with radiation-sparing regimens including intraventricular methotrexate. Neuro-Oncology, 2022, 24, i114-i115.	1.2	0
26	HGG-45. Characterization of spinal diffuse midline gliomas, H3 K28M-mutant. Neuro-Oncology, 2022, 24, i71-i71.	1.2	0
27	DIPG-42. Diffuse midline gliomas, H3K27-altered as an interdisciplinary challenge. Neuro-Oncology, 2022, 24, i28-i28.	1.2	0
28	ATRT-08. SMARCB1- and SMARCA4-deficient malignant brain tumors with complex copy number alterations and*TP53* mutations may represent the first clinical manifestation of Li-Fraumeni syndrome. Neuro-Oncology, 2022, 24, i4-i4.	1.2	0
29	MEDB-12. Severe developmental abnormalities and proliferative cerebellar lesions induced by combined activity of Wnt signalling and loss of SMARCA4. Neuro-Oncology, 2022, 24, i106-i106.	1.2	0
30	MEDB-67. Subgroup specific analysis of cellular metabolism in medulloblastoma. Neuro-Oncology, 2022, 24, i122-i122.	1.2	1
31	LGG-20. Defining subgroups in low grade gliomas by their immune and stromal microenvironment. Neuro-Oncology, 2022, 24, i92-i92.	1.2	0
32	ATRT-15. Primordial germ cells identified as one potential cell of origin of MYC rhabdoid tumors. Neuro-Oncology, 2022, 24, i6-i6.	1.2	0
33	MODL-03. Establishment of intraventricular Shh inhibition as a therapeutic option for young patients with medulloblastoma. Neuro-Oncology, 2022, 24, i168-i168.	1.2	0
34	EPEN-27. Epigenetic dissection of spinal ependymomas (SP-EPN) separates tumors with and without*NF2* mutation. Neuro-Oncology, 2022, 24, i44-i45.	1.2	0
35	ATRT-09. Outcome and therapeutic interventions in relapsed and refractory ATRT â€" The EU-RHAB perspective. Neuro-Oncology, 2022, 24, i4-i4.	1.2	2
36	MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT/non-SHH medulloblastoma despite highly intensified chemotherapy â€" Results of the MET-HIT2000-BIS4 trial. Neuro-Oncology, 2022, 24, i104-i104.	1.2	1

#	Article	IF	Citations
37	PATH-04. Array-based global DNA Methylation profiling of mouse brain tumors allows comparison to human tumors. Neuro-Oncology, 2022, 24, i158-i159.	1.2	0
38	RARE-15. Astroblastoma, *MN1* altered comprises two molecularly and clinically distinct subgroups defined by the fusion partners *BEND2* and *CXXC5*. Neuro-Oncology, 2022, 24, i12-i13.	1.2	1
39	MEDB-11. MYC overexpression and SMARCA4 loss in cerebellar granule cell precursors cooperate to drive medulloblastoma formation in mice. Neuro-Oncology, 2022, 24, i106-i106.	1.2	0
40	EPEN-04. Refinement of molecular and clinical characteristics in a cohort of 1,801 ependymomas. Neuro-Oncology, 2022, 24, i38-i39.	1.2	0
41	EPEN-06. Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease. Neuro-Oncology, 2022, 24, i39-i39.	1.2	0
42	OLIG2 Is a Determinant for the Relapse of *MYC*-Amplified Medulloblastoma. Clinical Cancer Research, 2022, 28, 4278-4291.	7.0	3
43	Circulating cell-free DNA and its clinical utility in cancer. Laboratoriums Medizin, 2022, 46, 265-272.	0.6	2
44	Ependymoma relapse goes along with a relatively stable epigenome, but a severely altered tumor morphology. Brain Pathology, 2021, 31, 33-44.	4.1	8
45	Detailed Clinical and Histopathological Description of 8 Cases of Molecularly Defined CNS Neuroblastomas. Journal of Neuropathology and Experimental Neurology, 2021, 80, 52-59.	1.7	18
46	An extracellular vesicle-related gene expression signature identifies high-risk patients in medulloblastoma. Neuro-Oncology, 2021, 23, 586-598.	1.2	8
47	Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases. Acta Neuropathologica, 2021, 141, 291-301.	7.7	47
48	Accurate calling of *KIAA1549–BRAF* fusions from DNA of human brain tumours using methylation array-based copy number and gene panel sequencing data. Neuropathology and Applied Neurobiology, 2021, 47, 406-414.	3.2	12
49	Mutations within FGFR1 are associated with superior outcome in a series of 83 diffuse midline gliomas with H3F3A K27M mutations. Acta Neuropathologica, 2021, 141, 323-325.	7.7	20
50	DIMEimmune: Robust estimation of infiltrating lymphocytes in CNS tumors from DNA methylation profiles. OncoImmunology, 2021, 10, 1932365.	4.6	17
51	Oncolytic Virus Therapy Alters the Secretome of Targeted Glioblastoma Cells. Cancers, 2021, 13, 1287.	3.7	8
52	Cauda equina paragangliomas express HOXB13. Neuropathology and Applied Neurobiology, 2021, 47, 889-890.	3.2	9
53	Neurofibromatosis type 2 predisposes to ependymomas of various localization, histology, and molecular subtype. Acta Neuropathologica, 2021, 141, 971-974.	7.7	12
54	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion–Positive Supratentorial Ependymomas. Cancer Discovery, 2021, 11, 2230-2247.	9.4	39

#	Article	IF	Citations
55	Evidence for a low‐penetrant extended phenotype of rhabdoid tumor predisposition syndrome type 1 from a kindred with gain of *SMARCB1* exon 6. Pediatric Blood and Cancer, 2021, 68, e29185.	1.5	0
56	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro-Oncology, 2021, 23, 1597-1611.	1.2	22
57	Malignant gliomas with H3F3A G34R mutation or MYCN amplification in pediatric patients with Li Fraumeni syndrome. Acta Neuropathologica, 2021, 142, 591-593.	7.7	5
58	Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors. Pediatric Blood and Cancer, 2021, 68, e29267.	1.5	7
59	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. Acta Neuropathologica, 2021, 142, 827-839.	7.7	33
60	Double adenomas of the pituitary reveal distinct lineage markers, copy number alterations, and epigenetic profiles. Pituitary, 2021, 24, 904-913.	2.9	4
61	Simultaneous Brg1 Knockout and MYCN Overexpression in Cerebellar Granule Neuron Precursors Is Insufficient to Drive Tumor Formation but Temporarily Enhances their Proliferation and Delays their Migration. Cerebellum, 2021, 20, 410-419.	2.5	4
62	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	12.8	237
63	Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification. Neuro-Oncology, 2021, 23, 1087-1099.	1.2	59
64	Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study. Neuro-Oncology, 2021, 23, 1012-1023.	1.2	19
65	Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies. Journal of Neuro-Oncology, 2021, 155, 193-202.	2.9	6
66	CD73-mediated adenosine production by CD8 T cell-derived extracellular vesicles constitutes an intrinsic mechanism of immune suppression. Nature Communications, 2021, 12, 5911.	12.8	66
67	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. Journal of Clinical Oncology, 2021, 39, 3839-3852.	1.6	93
68	Analysis of Intracerebroventricular (ICV) Device Function and Integrity under Long-Term ICV-ERT in CLN2 Patients. Neuropediatrics, 2021, 52, .	0.6	0
69	Co-activation of Sonic hedgehog and Wnt signaling in murine retinal precursor cells drives ocular lesions with features of intraocular medulloepithelioma. Oncogenesis, 2021, 10, 78.	4.9	0
70	PATH-31. METHYLATION SUBCLASS RECEPTOR TYROSINE KINASE II AS A DRIVER FOR SEIZURES IN IDH-WILDTYPE GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi121-vi122.	1.2	0
71	TMOD-25. LATENT SOX9-POSITIVE CELLS BEHIND MYC-DRIVEN MEDULLOBLASTOMA RELAPSE. Neuro-Oncology, 2021, 23, vi220-vi221.	1.2	0
72	BIOM-19. DECIPHERING THE METHYLATION SIGNATURE OF CIRCULATING EXTRACELLULAR VESICLE DNA FOR CNS TUMOR CLASSIFICATION. Neuro-Oncology, 2021, 23, vi14-vi14.	1.2	0

#	Article	IF	Citations
73	PATH-34. MOLECULAR AND CLINICAL HETEROGENEITY WITHIN SPINAL EPENDYMOMAS. Neuro-Oncology, 2021, 23, vi122-vi122.	1.2	0
74	EXTH-70. ESTABLISHMENT OF INTRAVENTRICULAR SHH INHIBITION AS A THERAPEUTIC OPTION IN YOUNG PATIENTS WITH MEDULLOBLASTOMA. Neuro-Oncology, 2021, 23, vi179-vi179.	1.2	1
75	TMOD-26. MYC OVEREXPRESSION AND SMARCA4 LOSS IN GRANULE CELL PRECURSORS COOPERATE TO DRIVE MEDULLOBLASTOMA FORMATION IN MICE. Neuro-Oncology, 2021, 23, vi221-vi221.	1.2	0
76	EXTH-69. FUNCTIONAL GENOMICS UNCOVER GENETIC DEPENDENCIES IN ATRTS. Neuro-Oncology, 2021, 23, vi179-vi179.	1.2	0
77	Brahma-related gene 1 has time-specific roles during brain and eye development. Development (Cambridge), 2021, 148, .	2.5	5
78	Enhancing Safety in Epilepsy Surgery (EASINESS): Study Protocol for a Retrospective, Multicenter, Open Registry. Frontiers in Neurology, 2021, 12, 782666.	2.4	1
79	Mass Spectrometric Lipid Profiles of Picosecond Infrared Laser–Generated Tissue Aerosols Discriminate Different Brain Tissues. Lasers in Surgery and Medicine, 2020, 52, 228-234.	2.1	5
80	Preferential sensitivity to HDAC inhibitors in tumors with CREBBP mutation. Cancer Gene Therapy, 2020, 27, 294-300.	4.6	29
81	Decision-making in temporal lobe epilepsy surgery based on invasive stereo-electroencephalography (sEEG). Neurosurgical Review, 2020, 43, 1403-1408.	2.4	6
82	Molecular characterization of histopathological ependymoma variants. Acta Neuropathologica, 2020, 139, 305-318.	7.7	43
83	The basic helix–loop–helix transcription factor TCF4 impacts brain architecture as well as neuronal morphology and differentiation. European Journal of Neuroscience, 2020, 51, 2219-2235.	2.6	16
84	Macrophage-tumor cell interaction promotes ATRT progression and chemoresistance. Acta Neuropathologica, 2020, 139, 913-936.	7.7	24
85	Immune Characterization in Aneurysmal Subarachnoid Hemorrhage Reveals Distinct Monocytic Activation and Chemokine Patterns. Translational Stroke Research, 2020, 11, 1348-1361.	4.2	32
86	Features of tumor texture influence surgery and outcome in intracranial meningioma. Neuro-Oncology Advances, 2020, 2, vdaa113.	0.7	4
87	Quantification of extracellular vesicles *in vitro* and *in vivo* using sensitive bioluminescence imaging. Journal of Extracellular Vesicles, 2020, 9, 1800222.	12.2	114
88	Immune Escape Mediated by Exosomal PD–L1 in Cancer. Advanced Biology, 2020, 4, e2000017.	3.0	19
89	Initial pupil status is a strong predictor for in-hospital mortality after aneurysmal subarachnoid hemorrhage. Scientific Reports, 2020, 10, 4764.	3.3	19
90	FASN Is a Biomarker Enriched in Malignant Glioma-Derived Extracellular Vesicles. International Journal of Molecular Sciences, 2020, 21, 1931.	4.1	20

#	Article	IF	Citations
91	Genome-wide DNA methylation profiles distinguish silent from non-silent ACTH adenomas. Acta Neuropathologica, 2020, 140, 95-97.	7.7	7
92	Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape. Acta Neuropathologica Communications, 2020, 8, 28.	5.2	24
93	Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. Journal of Clinical Oncology, 2020, 38, 2028-2040.	1.6	58
94	OUP accepted manuscript. Cerebral Cortex, 2020, 30, 1382-1392.	2.9	4
95	EPEN-09. IMPACT OF MOLECULAR SUBGROUP ON OUTCOME FOR INFANTS <12 MONTHS WITH INTRACRANIAL EPENDYMOMA - GERMAN EXPERIENCE FROM HIT2000, INTERIM-2000-REGISTRY AND I-HIT-MED REGISTRY. Neuro-Oncology, 2020, 22, iii309-iii309.	1.2	0
96	ATRT-13. DIFFERENT CELLS OF ORIGIN PAVE THE WAY FOR MOLECULAR HETEROGENEITY IN RHABDOID TUMORS. Neuro-Oncology, 2020, 22, iii278-iii278.	1.2	0
97	MBRS-10. QUIESCENT SOX9-POSITIVE CELLS BEHIND MYC DRIVEN MEDULLOBLASTOMA RECURRENCE. Neuro-Oncology, 2020, 22, iii400-iii400.	1.2	0
98	MBCL-06. RISK STRATIFICATION IMPROVEMENT OF THE HIT2000 AND I-HIT-MED COHORTS USING MOLECULAR SUBTYPES I-VIII OF GROUP 3/4 MEDULLOBLASTOMAS. Neuro-Oncology, 2020, 22, iii388-iii388.	1.2	0
99	Seizures as presenting symptom in patients with glioblastoma. Epilepsia, 2019, 60, 149-154.	5.1	22
100	Immunologic Profiling of Mutational and Transcriptional Subgroups in Pediatric and Adult High-Grade Gliomas. Cancer Immunology Research, 2019, 7, 1401-1411.	3.4	35
101	Machine learning analysis of DNA methylation profiles distinguishes primary lung squamous cell carcinomas from head and neck metastases. Science Translational Medicine, 2019, 11, .	12.4	100
102	Fatal Myelotoxicity Following Palliative Chemotherapy With Cisplatin and Gemcitabine in a Patient With Stage IV Cholangiocarcinoma Linked to Post Mortem Diagnosis of Fanconi Anemia. Frontiers in Oncology, 2019, 9, 420.	2.8	14
103	TCF4 (E2-2) harbors tumor suppressive functions in SHH medulloblastoma. Acta Neuropathologica, 2019, 137, 657-673.	7.7	20
104	Predictive factors associated with ventriculoperitoneal shunting after posterior fossa tumor surgery in children. Child's Nervous System, 2019, 35, 779-788.	1.1	11
105	Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours. Journal of Extracellular Vesicles, 2019, 8, 1588555.	12.2	86
106	Relapse of a group 4 medulloblastoma after 18Âyears as proven by histology and DNA methylation profiling. Child's Nervous System, 2019, 35, 1029-1033.	1.1	1
107	CSIG-09. PROTEOMIC ANALYSIS OF MENINGIOMA CELL-DERIVED EXTRACELLULAR VESICLES: FIRST OF A KIND. Neuro-Oncology, 2019, 21, vi45-vi46.	1.2	0
108	CSIG-11. CENTRAL NERVOUS SYSTEM TUMOR PATIENTS HAVE ELEVATED LEVELS OF CIRCULATING EXTRACELLULAR VESICLES. Neuro-Oncology, 2019, 21, vi46-vi46.	1.2	0

#	Article	IF	Citations
109	MEDU-26. LATENT SOX9-POSITIVE CELLS RESPONSIBLE FOR MYC-DRIVEN MEDULLOBLASTOMA RECURRENCE. Neuro-Oncology, 2019, 21, ii108-ii109.	1.2	0
110	MNGI-02. FEATURES OF TUMOR TEXTURE INFLUENCE SURGERY AND OUTCOME IN INTRACRANIAL MENINGIOMA. Neuro-Oncology, 2019, 21, vi139-vi139.	1.2	0
111	Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. Oncologist, 2019, 24, e921-e929.	3.7	19
112	Cytomegalovirus promotes murine glioblastoma growth via pericyte recruitment and angiogenesis. Journal of Clinical Investigation, 2019, 129, 1671-1683.	8.2	52
113	Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Science Advances, 2018, 4, eaar2766.	10.3	416
114	Germline variants in SMARCB1 and other members of the BAF chromatin-remodeling complex across human disease entities: a meta-analysis. European Journal of Human Genetics, 2018, 26, 1083-1093.	2.8	30
115	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
116	Group 3 medulloblastoma in a patient with a GYS2 germline mutation and glycogen storage disease 0a. Child's Nervous System, 2018, 34, 581-584.	1.1	2
117	CBMT-12. FATTY ACID SYNTHASE POSITIVE EVs AS NOVEL BIOMARKERS IN BRAIN CANCER.. Neuro-Oncology, 2018, 20, vi34-vi35.	1.2	0
118	TMOD-35. CAN RARE SOX9-POSITIVE CELLS INCITE MYC-DRIVEN MEDULLOBLASTOMA RECURRENCE?. Neuro-Oncology, 2018, 20, vi276-vi276.	1.2	0
119	Subgroup-specific immune and stromal microenvironment in medulloblastoma. OncoImmunology, 2018, 7, e1462430.	4.6	77
120	Coâ€occurrence of schwannomatosis and rhabdoid tumor predisposition syndrome 1. Molecular Genetics & Genomic Medicine, 2018, 6, 627-637.	1.2	13
121	NFM-11. PEDIATRIC MENINGIOMAS ARE MOLECULARLY DISTINCT FROM ADULT COUNTERPARTS. Neuro-Oncology, 2018, 20, i144-i145.	1.2	1
122	ATRT-21. COMPARATIVE INTEGRATIVE ANALYSIS OF PRIMARY AND RELAPSED ATYPICAL TERATOID/RHABDOID TUMORS (AT/RTs). Neuro-Oncology, 2018, 20, i32-i32.	1.2	0
123	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. Acta Neuropathologica, 2018, 136, 327-337.	7.7	104
124	ATOH1 Promotes Leptomeningeal Dissemination and Metastasis of Sonic Hedgehog Subgroup Medulloblastomas. Cancer Research, 2017, 77, 3766-3777.	0.9	29
125	MicroRNA Signatures and Molecular Subtypes of Glioblastoma: The Role of Extracellular Transfer. Stem Cell Reports, 2017, 8, 1497-1505.	4.8	58
126	MicroRNA-Mediated Dynamic Bidirectional Shift between the Subclasses of Glioblastoma Stem-like Cells. Cell Reports, 2017, 19, 2026-2032.	6.4	33

#	Article	IF	Citations
127	Medulloblastoma: experimental models and reality. Acta Neuropathologica, 2017, 134, 679-689.	7.7	25
128	IMMU-10. EXPRESSION OF PD-L2, IN GLIOBLASTOMA; IMPLICATIONS AS AÂBIOMARKER FOR IMMUNOTHERAPY. Neuro-Oncology, 2017, 19, vi114-vi114.	1.2	0
129	CBIO-12. SIX EXTRACELLULAR VESICLE RELATED GENES CAN EXPLAIN THE PRO-TUMORIGENIC BEHAVIOR OF HETEROGENEOUS HIGH GRADE GLIOMAS. Neuro-Oncology, 2016, 18, vi37-vi37.	1.2	0
130	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	16.8	191
131	Extracellular Vesicles from High-Grade Glioma Exchange Diverse Pro-oncogenic Signals That Maintain Intratumoral Heterogeneity. Cancer Research, 2016, 76, 2876-2881.	0.9	85
132	The Long Non-coding RNA HIF1A-AS2 Facilitates the Maintenance of Mesenchymal Glioblastoma Stem-like Cells in Hypoxic Niches. Cell Reports, 2016, 15, 2500-2509.	6.4	156
133	The simplified acute physiology score II to predict hospital mortality in aneurysmal subarachnoid hemorrhage. Acta Neurochirurgica, 2015, 157, 2051-2059.	1.7	10
134	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncology, The, 2013, 14, 1200-1207.	10.7	307
135	Acquisition of Granule Neuron Precursor Identity Is a Critical Determinant of Progenitor Cell Competence to Form Shh-Induced Medulloblastoma. Cancer Cell, 2008, 14, 123-134.	16.8	572